amfAR, The Foundation for AIDS Research
TREAT Asia (Therapeutics Research, Education,
and AIDS Training in Asia) is a network of clinics, hospitals, and research
institutions working with civil society to ensure the safe and effective
delivery of HIV/AIDS treatments throughout Asia and the Pacific.
Are integrase inhibitors the solution to HIV drug resistance in the Asia-Pacific region?
... of adolescents from pediatric to adult HIV care
What should be the highest priority in 2018 for ending AIDS in the Asia-Pacific region?
The TREAT Asia Report Interview: Dr. Praphan Phanuphak
Stigma and HIV reinforce one another and fan the flames of the HIV/AIDS epidemic.
The TREAT Asia Report Interview: Eamonn Murphy, UNAIDS Director, Regional Support Team for Asia and the Pacific
Get regular email updates and analysis about the most pressing AIDS-related issues facing the Asia-Pacific region.
Dolutegravir (DTG) is a well-tolerated antiretroviral drug that is increasingly recognized as a potential first-line option for the treatment of HIV. This clinical brief is available in English, Bahasa Indonesia, Chinese Mandarin, Japanese, Khmer, Korean, Malay, Thai and Vietnamese.
Working with experts from New York City’s Columbia University, regional clinicians and researchers met to address the depression that disproportionately affects those living with HIV in the Asia-Pacific.
The Thai Network of People Living with HIV/AIDS and AIDS Access Foundation urge employers to focus on job candidates’ abilities and qualifications, not their HIV status.
© 2018 amfAR All Rights Reserved